Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is a direct-acting, reversible, P2Y12 platelet inhibitor used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of cardiovascular death, MI, and stroke in patients with ACS.
* **Myocardial Infarction (MI):** In patients with a history of MI (at least 1 year prior) with at least one other cardiovascular risk factor, to reduce the rate of cardiovascular death, MI, and stroke.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or until advised otherwise by a physician.
* **Alternative Maintenance Dose (in specific populations after 12 months, e.g., older patients or those with lower risk of ischemic events but higher risk of bleeding):** 60 mg orally twice daily.
* **History of MI (at least 1 year prior):** 60 mg orally twice daily.
## Pediatric Dosing
Dosing for pediatric patients has not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is recommended.
* **Hepatic Impairment:** No dose adjustment is recommended; however, caution is advised in patients with severe hepatic impairment.
## Contraindications
* Active bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Dyspnea, bradycardia, bleeding (including fatal and serious hemorrhage), contusion.
* **Serious:** Life-threatening bleeding, ventricular pauses, increased serum creatinine.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor exposure.
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with CYP3A4 substrates (e.g., simvastatin, lovastatin) may increase exposure to these drugs.
* **Aspirin:** Generally used in combination with aspirin, but the dose of aspirin for maintenance therapy should be ≤ 100 mg. Higher doses of aspirin may reduce the efficacy of ticagrelor and increase bleeding risk.
* **Other Antiplatelets/Anticoagulants:** Use with caution due to increased risk of bleeding.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Renal Function:** Monitor serum creatinine.
* **Electrolytes:** Monitor serum uric acid levels.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, which may be advantageous in patients requiring urgent surgery compared to irreversible inhibitors.
* Dyspnea is a common side effect and usually not clinically significant; however, it should be evaluated to rule out other causes.
* Discontinuation of ticagrelor should be avoided if possible, as it increases the risk of thrombotic events. If discontinuation is necessary, resume as soon as possible.
* Ticagrelor can be taken with or without food.
***
**Disclaimer:** This information is intended for clinical use and does not substitute for professional medical judgment. Always refer to the most current prescribing information and consult with a healthcare professional for patient-specific guidance.
